12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daclatasvir: Additional Phase IIa data

Additional data from 16 treatment-naïve, non-cirrhotic patients with HCV genotype 1 infection in Part 1 of an open-label, international Phase IIa trial showed that an oral regimen of asunaprevir, daclatasvir and BMS-791325 for 12 weeks produced an SVR defined as undetectable HCV RNA levels (<25 IU/mL) 12 weeks after end of treatment in 94% of patients. Bristol-Myers said the 1 patient was lost to follow-up after completing treatment...

Read the full 328 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >